Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
Related Experiment Video
Updated: Jan 27, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Praveen K Bommareddy1,2, Samuel D Rabkin3, Howard L Kaufman4,5
1Department of Surgery, Graduate School of Biomedical Sciences, New Brunswick, USA.
Abstract:
In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy increased PD-1/PD-L1 expression and PD-1 blockade further enhanced tumor regression. Further clinical development of this strategy for treating melanomas warranted.
Related Concept Videos
Stereotype Threat and Self-fulfilling Prophecies
Neuromuscular Junction And Blockade
Threats to Biodiversity
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

